Margenza (margetuximab) won FDA approval in combination with chemotherapy to treat metastatic HER2-positive breast cancer after at least two previous rounds of therapy.

Revenue from Collaborative and Other Agreements: $118.9 million. MARGENZA Net Sales: $16.4 million. Contract Manufacturing Revenue: $13.1 million. Research and Development Expenses: $177.2 million ...